Viridans streptococci were the most common cause of bacteremia in 61 consecutive myeloablative allogeneic hematopoietic stem cell transplant (HSCT) recipients, occurring in 19 of 31 bacteremic patients (61%) during the period of post-transplant neutropenia. Seven of the 19 had more than one viridans streptococcus in the same blood culture. Twenty isolates from 15 patients were Streptococcus mitis. Most viridans streptococci were resistant to norfloxacin, used routinely for prophylaxis. Comparison of the 19 patients with viridans streptococcal bacteremia with a contemporaneous group of 23 allogeneic HSCT recipients with fever and neutropenia but no identified focus of infection found that patients with viridans streptococcal bacteremia were more likely to have severe intraoral pathology while neutropenic (26% vs 0%) and slightly shorter interval between the last dental procedure and the onset of neutropenia (11 vs 14 days). Poor underlying dental health and the use of norfloxacin thus appear to predispose to viridans streptococcal bacteremia. Bone Marrow Transplantation (2001) 27, 537-542.
The past decade has seen a change from Gram negative to Gram positive organisms as a cause of bacteremia in neutropenic patients. 1 Staphylococcus epidermidis has been the Gram positive bacterium 2 most frequently encountered, largely due to increased use of intravascular catheters. 3, 4 Viridans streptococci, which are oral commensals, have also been reported to cause bacteremia and may cause adult respiratory distress syndrome, shock, or endocarditis. [5] [6] [7] Factors reported to be associated with viridans streptococcal bacteremia have been oral mucositis, 5, 6, 8 high-dose cytosine arabinoside, 9 younger age, 10 and antibiotic prophy- laxis with fluoroquinolones which have poor Gram positive activity. 11 The impact of dental health as a risk factor for viridans streptococcus infection is not known.
Patients and methods

Patient characteristics
Medical charts and dental records were reviewed of 61 consecutive patients with hematological malignancies receiving myeloablative allogeneic HSCT at the National Heart, Lung and Blood Institute in the 21-month period from January 1997 to October 1999 (NIH protocols 93-H-0212, 94-H-0092, 97-H-0099, 98-H-0122, 99-H-0046).
The conditioning regimen during the pre-transplant period was usually total body irradiation followed by two infusions of high-dose cyclophosphamide (60 mg/kg i.v.). Two patients received busulfan in place of total body irradiation or fludarabine instead of cyclophosphamide. Cyclosporine was also given to approximately half of the 61 cases. Norfloxacin 400 mg p.o. twice a day was begun 7-10 days prior to transplantation and continued until the patient's neutrophil count was sustained above 1000 cells/l. Weekly trimethoprim-sulfamethoxazole prophylaxis for Pneumocystis carinii pneumonia was started on day 30 post-transplant or upon discharge from hospital. Acyclovir was given until 30 days after transplantation as prophylaxis against herpesvirus infections. Intravenous immunoglobulin 0.5 g/kg was given weekly for the first 100 days post transplant. G-CSF 5.0 g/kg/day was given from day 7 post-transplant until the neutrophil count exceeded 1 × 10 9 /l for 3 consecutive days or until day 21 post-transplant. The first two patients received infusions of donor bone marrow cells; the others received stem cells harvested from peripheral blood.
Blood cultures
Most blood cultures were drawn from intravenous catheters. An 8-10 ml blood sample was inoculated into an Isolator tube (Wampole, Cranbury, NJ, USA) and 3-5 ml into a blood culture bottle (BacTAlert, Organon Teknika, Dur-ham, NC, USA). Isolator concentrate was inoculated on to five plates (two chocolate agar, two blood agar and one brain heart infusion agar) incubated aerobically with 5% CO 2 . Plates and bottles were incubated for 5 days before considered negative.
Organism identification and antibiotic susceptibility testing
Alpha hemolytic or nonhemolytic streptococci were identified using a composite of phenotypic characteristics and biochemical reactions included in the API 20 Strep identification panel (bioMerieux, Marcy L'Etoile, France) as well as additional biochemical testing as needed. The identifications were the closest individual species designations that could be determined and not the broader group designations recently proposed. 12 All isolates were tested for antimicrobial susceptibility using the Etest method (AB BioDisk, Solna, Sweden). Multiple strains of the same streptococcal species isolated in the same culture were differentiated by colony morphology and subsequent antibiotic resistance patterns.
Analysis of dental health
Fifty-six of the 61 patients were evaluated in the dental clinic before transplantation with a complete dental examination and panographic radiograph. Caries were diagnosed by clinical examination and appropriate bite wing and periapical radiographs. Alveolar bone loss (a measure of cumulative periodontal disease) was calculated from panographic radiographics with the aid of a Schei ruler. 13 The number of days between any dental treatment and the onset of neutropenia was documented. Nineteen of the 56 patients had bacteremia from viridans streptococcus. In order not to confound our results and ensure a relatively homogenous control group, 14 patients with documented infection or bacteremia during neutropenia were excluded, leaving 23 of the remaining 37 patients to serve as controls to analyze for dental risk factors for viridans streptococcal bacteremia. While the reviewer of the patients' dental records was aware of the patients' microbiological status, possible dental risk factors were determined prior to dental chart review. Characteristics of patients with viridans streptococcal bacteremia and case controls are given in Table 1 . There were no significant differences between the two groups.
Statistical analysis
Fisher's exact test was used to compare nominal independent variables, Mann-Whitney analysis was used to compare ordinal independent variables, and Student's t-test was used to compare continuous independent variables for cases and case controls. The first day of neutropenia was defined as the first day the patient's absolute neutrophil count fell below 500 cells/l coincident with or following the first day of the conditioning regimen. Neutropenia was considered resolved when the absolute neutrophil count was greater than 500 cells/l for at least 2 consecutive days (the first of these dates was recorded as the date of neutropenia resolution). b Fever was generally defined as the patient's first recorded temperature of 38.0°C or above while neutropenic that was deemed to require antibiotic therapy. Resolution of fever was defined by at least 48 continuous hours of recorded temperatures less than 38.0°C. Only the first febrile episode during the neutropenic period was included in this analysis. Mucositis was defined by the presence of oral lesions or erythema on physical examination or mouth and/or throat pain requiring parenteral analgesia. Records from three control patients were insufficient to determine the presence or lack of mucositis.
Results
Causes of bacteremia
All 61 patients in this cohort had fever during neutropenia, 31 accompanied by a positive blood culture. Gram negative bacteria were isolated in only three episodes (two Escherichia coli and one Capnocytophaga species). In two of these episodes, Gram positive organisms were also isolated. 
Severity of viridans streptococcal bacteremia
Eighteen of 19 patients with viridans streptococcal bacteremia responded promptly to treatment with ceftazidime and vancomycin. One patient developed septic shock and acute respiratory distress accompanied by a blood culture positive for S. mitis. She was admitted to the intensive care unit the following day and required ventilatory support. Although the septicemia responded promptly to antibiotic therapy, she failed to improve clinically, remained on the ventilator, and died 5 weeks later from multiple organ failure. In all patients, viridans streptococci were isolated from blood only once during the period of post-transplant neutropenia, and the median duration of fever in the patients with viridans streptococcal bacteremia was 3 days.
Antimicrobial susceptibility of viridans streptococci
The antimicrobial susceptibility of the 26 viridans streptococcus isolates are shown in Table 2 . All isolates were sensitive to vancomycin (MIC range 0.38-1 g/ml), despite one patient having received 4 days of vancomycin therapy that was discontinued 12 days prior to bacteremia. Most isolates were sensitive to ceftriaxone (MIC range 0.004-12 g/ml), but three isolates, all S. mitis, were resistant. In two of these three episodes, the patient had received a cephalosporin in the previous 2 weeks. One patient had a 5-day course of cefazolin discontinued approximately 1 week prior to bacteremia, and one patient had been receiving ceftazidime for 12 days and was still receiving ceftazidime at the time of bacteremia. Overall susceptibility to penicillin (MIC range 0.004 to 12 /ml) was comparable to that of ceftriaxone. The majority of isolates tested were resistant (MIC range 2 to Ͼ256 g/ml) to norfloxacin. Notably, the two strains that were most resistant to ceftriaxone (the same two strains in which the patient had received a cephalosporin in the 2 weeks prior to bacteremia) were the most resistant to norfloxacin (MIC Ͼ256 g/ml) as well.
Intraoral pathology
Dental characteristics and procedures performed on cases of viridans streptococcal bacteremia and case controls are summarized in Table 3 . The necessity for dental extractions in 20 of 42 patients and the fact that 31 of the 42 patients presented with dental caries on initial examination was characteristic of this patient population. In six patients (three cases and three controls), impacted wisdom teeth communicating with the oral cavity were removed because they were potential sources of infection. In seven cases and eight controls, teeth were extracted because of advanced caries or periodontal disease (one control patient had an impacted third molar removed prophylactically and had another tooth removed because of advanced periodontal disease).
Five of the 19 patients with viridans streptococcal bacteremia had severe intraoral pathology, defined a priori as a loss of integrity of the alveolar mucosa and bone, at the time of neutropenia versus none of the 23 case controls (P = 0.014). This result was significant even when considering that multiple comparisons were made in this study. Three of the five patients had an unhealed extraction site as evidenced by continued pain in the extraction site after the onset of neutropenia (two patients) or clinical evidence of an open site during neutropenia (one). One of these patients, who had chronic myelogenous leukemia in accelerated phase, had a granuloma at the site of extraction found to contain leukemic cells on biopsy. Two other patients had multiple carious teeth exhibiting periapical abscesses on pre-transplant dental radiographs. These abscesses, which had eroded significant bone at the apices of the teeth, were not treated before myeloablative therapy was started because of the urgency of the transplant procedure. Radiographs exhibiting multiple periapical abscesses of the posterior maxillary teeth of one of these patients (UPN 103) are shown in Figure 1 . The patients with viridans streptococcal bacteremia also had a shorter (although not statistically significant) time period between the last dental procedure performed and the onset of neutro- penia. The days on which all the dental procedures were performed and the day of positive blood culture for the S. viridans group are summarized in Table 4 . As noted in Table 1 , most patients in both groups had some degree of mucositis during the first 7-10 days post-transplant.
Discussion
The incidence of post-transplant neutropenic viridans streptococcal bacteremia in our myeloablative allogeneic HSCT population is high (19 of 61 patients, 31%) and exceeds the incidence reported in other centers. 9, 15, 16 Other centers also report a higher incidence of coagulase-negative staphylococci relative to that of viridans streptococci. With regard to the shock syndrome reported for neutropenic cancer patients with viridans streptococcal bacteremia, 7, 17 it is important to note that only one patient in our series developed septic shock, which contributed to her death from multiple organ failure 5 weeks later.
Several factors may account for the high incidence of viridans streptococcal bacteremia at our institution. Firstly, the preparative regimen of cyclophosphamide and total body irradiation leads to significant mucositis. Secondly, the choice of quinolone prophylaxis may have favored viridans streptococcal bacteremia. Norfloxacin was initially 541 Table 4 Dental treatment received by patients who developed neutropenic viridans streptococcal bacteremia chosen as prophylaxis for these patients to protect against Gram negative infections and to reduce aerobic Gram negative bowel flora. However, it is relatively ineffective against Gram positive organisms, particularly viridans streptococci, as shown here. Even so, the MICs of several of the strains tested were higher than those typically reported for norfloxacin against streptococci, [18] [19] [20] and the two strains with the highest resistance to norfloxacin were the strains that had the highest resistance to ceftriaxone. These strains were isolated in the patients who received a cephalosporin within the 2 weeks prior to bacteremia in addition to norfloxacin prophylaxis. Similar resistance to beta-lactams 21, 22 and quinolones 23 have been reported in neutropenic cancer patients taking these agents. The incidence of penicillin resistance (MIC у4 g/ml) in our population (three of 26 isolates, 12%) is lower than that previously reported for viridans streptococci isolated from neutropenic cancer patients. 21 Finally, many of our patients were referred from countries where dental care is usually inadequate. As noted above, several past studies have suggested an association between chemotherapy-induced severe mucositis and viridans streptococcal bacteremia. These findings support the hypothesis that disruption of the mucosal barrier separating the body from resident oral flora is a risk factor for the acquisition of viridans bacteremia. Other oral pathology has received less attention as a possible portal for viridans streptococcal bacteremia. The finding in this study of five cases with a loss of integrity in the alveolar bone around the teeth (two from abscesses and three from unhealed extraction sites) suggests that an intact alveolar barrier is also important in preventing bacteremia with oral flora.
At our institution, it is policy to carry out a dental examination prior to transplantation and aggressively treat dental pathology when the pace of disease progression permits. Control of intraoral pathology prior to the onset of neutroBone Marrow Transplantation penia appears to be important. Only two of the 42 patients in this study started myeloablative treatment with periapical abscesses; both acquired viridans bacteremia. Both of these patients had progressive leukemia that required emergent transplantation. It was decided that invasive procedures to correct intraoral pathology would not be performed because there was not enough time between dental clinic visit and onset of neutropenia to ensure adequate healing.
Certainly, infected teeth should be removed before the onset of neutropenia if time permits. Other dental treatment needs, such as cleaning of the teeth, extractions of teeth with advanced caries or periodontal disease, and restorative procedures are carried out as the patient's condition permits according to published guidelines. 24, 25 However, the trend toward a shorter time period between dental procedures and neutropenia onset in patients with viridans streptococcal bacteremia suggests that such procedures should be performed well in advance of the anticipated transplant date. In particular, extractions should be done as soon as possible. Though published guidelines state that 10 days is adequate for healing after an extraction, two cases in this study (UPN 82 and 127) had very delayed healing of their extraction sites. Both patients had chronic myelogenous leukemia that recurred after transplantation, suggesting that their underlying malignancy delayed normal healing.
In general, the oral health needs of the patients in this study were extensive. Thirty-one had dental caries, often of multiple teeth, on initial examination. Several cases and controls had abscessed teeth that were detectable only on dental radiographs. Though the reasons for the extensive dental pathology cannot be determined from this small group, the fact that patients had persistent illness that necessitated hematopoietic stem cell transplantation was likely a contributing factor. Therefore, the oral health of patients should be assessed well in advance of myeloabl-ative transplant. The decision to correct intraoral pathology prior to transplantation should be based on the invasiveness of the procedures used to correct the pathology, as well as the time-frame between treatment and anticipated transplant date.
